LCI - Lannett Company, Inc.

NYSE - NYSE Delayed Price. Currency in USD
11.73
-0.22 (-1.84%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close11.95
Open11.95
Bid0.00 x 800
Ask0.00 x 800
Day's Range11.60 - 12.15
52 Week Range3.33 - 15.52
Volume692,505
Avg. Volume2,302,346
Market Cap473.959M
Beta (3Y Monthly)2.49
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire

    Bragar Eagel & Squire is Investigating Certain Officers and Directors of Lannett Company, LogMeIn, and Mammoth Energy and Encourages Investors to Contact the Firm

    NEW YORK, Oct. 04, 2019 -- Bragar Eagel & Squire is investigating certain officers and directors of Lannett Company, Inc. (NYSE: LCI), LogMeIn, Inc. (NASADQ: LOGM), and.

  • PR Newswire

    Lannett Enters Into Distribution Agreement For Generic ADVAIR DISKUS®

    PHILADELPHIA, Oct. 1, 2019 /PRNewswire/ -- Lannett Company, Inc. (LCI) today announced that it has entered into an exclusive U.S. distribution agreement for the therapeutically equivalent generic of ADVAIR DISKUS® (Fluticasone Propionate – Salmeterol Xinafoate Powder Inhaler) of Respirent Pharmaceuticals Co. Ltd.  ADVAIR DISKUS had U.S. sales of $3.6 billion for the 12 months ending July, 2019, according to IQVIA, although actual generic market values are expected to be lower. Under the agreement, Lannett will commence U.S. distribution of the product after FDA approval.  Lannett will make an upfront payment, as well as future milestone payments, and receive a portion of the net profits once it commences distribution of the product.  The term of the agreement is 10 years, which begins upon commencement of distribution.  Other terms were not disclosed.

  • PR Newswire

    Lannett Announces Closing Of $86.25 Million Of Convertible Senior Notes Due 2026

    PHILADELPHIA, Sept. 27, 2019 /PRNewswire/ -- Lannett Company, Inc. (LCI) ("Lannett" or the "Company") today announced the closing of $86.25 million aggregate principal amount  of 4.50% convertible senior notes due 2026 (the "Notes") in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Lannett granted the initial purchaser of the Notes a 30-day option to purchase up to an additional $11.25 million aggregate principal amount of the Notes, which option the initial purchaser exercised in full. "We are pleased to have successfully completed our recent convertible note offering that has strengthened our capital structure by replacing variable interest rate debt that matures in November 2020 with a substantially lower fixed interest rate convertible bond that matures in October 2026," said Tim Crew, chief executive officer of Lannett.

  • PR Newswire

    Lannett Announces pricing of $75 million of Convertible Senior Notes Due 2026

    PHILADELPHIA, Sept. 25, 2019 /PRNewswire/ -- Lannett Company, Inc. (LCI) ("Lannett" or the "Company") today announced the pricing of $75 million aggregate principal amount of 4.50% convertible senior notes due 2026 (the "Notes") in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Lannett also granted the initial purchaser of the Notes a 30-day option to purchase up to an additional $11.25 million aggregate principal amount of the Notes. The sale of the Notes to the initial purchaser is expected to settle on September 27, 2019, subject to customary closing conditions, and Lannett estimates that it will receive approximately $72.7 million in net proceeds (or $83.6 million if the initial purchaser exercises its option to purchase additional Notes in full) after deducting the initial purchaser's discount and estimated offering expenses payable by Lannett.

  • PR Newswire

    Lannett Announces Offering of $75 million of Convertible Senior Notes Due 2026

    PHILADELPHIA, Sept. 24, 2019 /PRNewswire/ -- Lannett Company, Inc. (LCI) today announced that it intends to offer, subject to market conditions and other factors, $75 million aggregate principal amount of convertible senior notes due 2026 (the "Notes") in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Lannett also intends to grant the initial purchaser of the Notes a 30-day option to purchase up to an additional $11.25 million aggregate principal amount of the Notes. Conversion of the Notes will be settled in shares of the Company's common stock.

  • PR Newswire

    Lannett Enters Into Distribution Agreement For Posaconazole Delayed-Release Tablets; Launch To Commence Shortly

    PHILADELPHIA, Aug. 28, 2019 /PRNewswire/ -- Lannett Company, Inc. (LCI) today announced that it has entered into an agreement with Sinotherapeutics Inc., a China-based specialty pharmaceutical company, to be the exclusive U.S. distributor of Posaconazole Delayed-Release Tablets 100mg.  Sinotherapeutics has received final approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Posaconazole Delayed-Release Tablets 100mg, which is an AB-rated generic equivalent of Merck's Noxafil® Delayed-Release Tablets.  Lannett expects to commence shipping the product shortly. The brand product's annual U.S. sales were approximately $325 million for the twelve months ended June 2019, according to IQVIA, although actual generic market values are expected to be lower.

  • PR Newswire

    Lannett Announces Fiscal 2019 Fourth-Quarter, Full-Year Financial Results; Issues Guidance For Fiscal 2020

    Fiscal 2019 Fourth Quarter Highlights: - Net Sales of $134 Million Exceeds Expectations - Adjusted Gross Margin Percentage Highest of Any Quarter in Fiscal 2019 - Voluntarily Purchased Additional $38 Million ...

  • PR Newswire

    Lannett Enters Into Advisory Services Agreement With Strategic Alliance Partner

    PHILADELPHIA, Aug. 27, 2019 /PRNewswire/ -- Lannett Company, Inc. (LCI) today announced that it has entered into a three-year advisory services agreement with its strategic alliance partner, Cediprof, Inc., a wholly owned subsidiary of privately held Neolpharma Group.  This agreement is separate and in addition to the supply and distribution agreement for Levothyroxine Sodium Tablets USP recently entered into by the companies.

  • PR Newswire

    Lannett To Report Fiscal 2019 Fourth-Quarter, Full-Year Financial Results, Host Conference Call On Tuesday, August 27

    PHILADELPHIA , Aug. 20, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2019 fourth quarter and full year on Tuesday, August ...

  • GlobeNewswire

    Bragar Eagel & Squire is Investigating Certain Officers and Directors of Lannett, Molson Coors, AxoGen, and American Renal Associates and Encourages Investors to Contact the Firm

    Bragar Eagel & Squire is investigating certain officers and directors of Lannett Company, Inc. (LCI), Molson Coors Brewing Company (TAP), AxoGen, Inc. (AXGN), and American Renal Associates Holdings, Inc. (ARA) on behalf of long-term stockholders. Bragar Eagel and Squire is investigating certain officers and directors of Lannett Company, Inc. following a class action complaint that was filed against Lannett on November 16, 2016.

  • PR Newswire

    Lannett Appoints John Kozlowski CFO

    PHILADELPHIA , Aug. 1, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced the appointment of John Kozlowski as chief financial officer (CFO), effective August 31 , 2019. He succeeds ...

  • ACCESSWIRE

    SHAREHOLDER ALERT: Shareholder Class Action Against Lannett Company (LCI) Survives Motion to Dismiss; The Law Offices of Timothy L. Miles Encourages Shareholders to Contact the Firm

    HENDERSONVILLE, TN / ACCESSWIRE / July 19, 2019 / The Law Offices of Timothy L. Miles , who has been leading the fight to protect shareholder rights for over 18 years, announces that Lannett Company (NYSE:LCI) ...

  • PR Newswire

    FDA Clears Path For The Continuing Review Of Lannett Company's New Drug Application

    PHILADELPHIA, July 3, 2019 /PRNewswire/ -- Lannett Company, Inc. (LCI) today commented on the U.S. Food and Drug Administration's (FDA) denial of a Citizen Petition submitted by Genus Lifesciences requesting that the FDA refuse to accept any submissions related to Lannett's 505(b)(2) New Drug Application (NDA) for Cocaine Hydrochloride Topical Solution, 4% and 10%.

  • PR Newswire

    Lannett Enters Into Distribution Agreement For Dantrolene Capsules, Commences Product Launch

    Dantrolene Capsules 25 mg, 50 mg and 100 mg is the therapeutic equivalent to the reference listed drug, Dantrium® Capsules 25 mg, 50 mg and 100 mg of Par Pharmaceuticals, Inc. (an Endo International Company). Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company which is developing a pipeline of proprietary pharmacological abuse-deterrent opioid products as well as niche generic products.

  • PR Newswire

    Lannett Launches Aspirin And Extended-Release Dipyridamole Capsules

    PHILADELPHIA , June 18, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has commenced marketing Aspirin and Extended-Release Dipyridamole Capsules, 25 mg/200 mg, the therapeutic ...

  • PR Newswire

    Lannett To Participate At Two Investor Conferences In June

    PHILADELPHIA , June 12, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced its participation at two upcoming investor conferences.  Schedule below: Raymond James 2019 Life Sciences ...

  • PR Newswire

    Lannett Announces Initiation Of Human Clinical Trial Of Biosimilar Insulin Glargine Versus Us Lantus®

    PHILADELPHIA, June 5, 2019 /PRNewswire/ -- Lannett Company, Inc. (LCI) today announced the commencement of a human clinical trial of biosimilar insulin glargine, a product the company is co-developing with its strategic alliance partners within the HEC Group of companies (HEC).  The trial, being conducted in South Africa, is the first clinical study to directly compare the Lannett/HEC insulin glargine to US Lantus® as part of the effort to file a biosimilar Biologics License Application with the U.S. Food and Drug Administration.  Insulin glargine is a long-acting insulin used to treat adults with Type 2 diabetes, as well as adults and pediatric patients with Type 1 diabetes, for the control of high blood sugar.

  • PR Newswire

    Lifshitz & Miller LLP Announces Investigation of A.O. Smith Corporation, Cray Inc., electroCore, Inc., Fred's Inc., Intersect ENT, Inc., Jumia Technologies AG, Lannett Company Inc., and Zayo Group Holdings, Inc.

    NEW YORK , May 30, 2019 /PRNewswire/ -- A.O. Smith Corporation (AOS) Lifshitz & Miller announces investigation into possible securities laws violations in connection with allegations questioning AOS' access ...

  • PR Newswire

    Lannett Commences Marketing Generic Concerta®

    PHILADELPHIA , May 29, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has commenced marketing Methylphenidate Hydrochloride Extended Release (ER) tablets USP (CII) in 18 ...

  • PR Newswire

    Lannett Announces CFO Retirement

    PHILADELPHIA, May 24, 2019 /PRNewswire/ -- Lannett Company, Inc. (LCI) today announced that the company's chief financial officer (CFO), Martin Galvan, 67, will retire on August 30, 2019, following the planned submission of the company's Form 10-K for fiscal year 2019. Lannett is conducting a search for its next CFO, which includes internal and external candidates, and has retained an executive search firm to assist in the process. "On behalf of the entire Board and management team, I thank Marty for his dedication and valuable contributions over his eight-year career at Lannett," said Tim Crew, chief executive officer of Lannett.

  • PR Newswire

    (LCI) Alert: Johnson Fistel, LLP Announces Investigation of Lannett Company, Inc.; Long Term Investors Encouraged to Contact Firm

    SAN DIEGO, May 23, 2019 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential violations of federal and state laws by Lannett Company, Inc. (LCI) ("Lannett")  and certain of its officers. In 2017 a securities class action lawsuit was filed on behalf of purchasers of the securities of Lannett from July 15, 2014 and October 31, 2017, (the "Class Period"). The complaint alleges that Defendants made false and misleading statements regarding the Company's drug pricing methodologies and internal controls.  On May 15, 2019, Judge Wendy Beetlestone denied defendants motion to dismiss.

  • PR Newswire

    Lannett Appoints Melissa V. Rewolinski, PhD, To Board Of Directors

    PHILADELPHIA , May 23, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced the appointment of Melissa V. Rewolinski , PhD, to its board of directors, effective July 1, 2019 . Following ...

  • Business Wire

    Haeggquist & Eck Investigates Conspiracy to Fix Prices on Generic Drugs by Lannett Officers and Directors

    Haeggquist & Eck, LLP, a leading shareholder rights litigation firm, is investigating whether certain officers and directors of Lannett Company, Inc. (“Lannett” or the “Company”) (LCI) breached their fiduciary duties to the Company and its shareholders. Lannett is a generic drug maker that grew quickly starting in 2013, largely due to big price increases. In fact, the price of its generic drug Digoxin, a life-saving heart failure drug, rose 857% from April 2013 to April 2015.

  • PR Newswire

    Lannett Purchases Additional $30.5 Million Of Term A Loans

    Crew noted that the company's solid financial performance over the last three quarters contributed to its ability to purchase the Term A Loans prior to maturity.  In March 2019, the company completed the purchase of approximately $24 million principal amount of its Term A and Term B Loans in open market transactions, bringing the total purchases of its Term Loans to approximately $55 million over the last three months.  These amounts are in addition to the company's required annual principal payments of approximately $67 million.